Other Events ·
Alterity Therapeutics CEO to present at Craig-Hallum Biotech Catalyst Conference on October 22
ATHEAlterity Therapeutics Ltd
David Stamler, Chief Executive Officer of Alterity Therapeutics, will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, October 22, 2026, at 2:30 p.m. ET. The company is preparing to initiate a Phase 3 pivotal trial for its lead asset, ATH434, in Multiple System Atrophy (MSA), following positive data from earlier clinical trials. Alterity Therapeutics Limited operates as a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases.